



THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### What can stem cell technology offer to IVF patients?

**Citation for published version:**

Ilic, D, Telfer, E, Ogilvie, C, Kolundzic, N & Khalaf, Y 2019, 'What can stem cell technology offer to IVF patients?', *BJOG: An International Journal of Obstetrics and Gynaecology*. <https://doi.org/10.1111/1471-0528.15638>

**Digital Object Identifier (DOI):**

[10.1111/1471-0528.15638](https://doi.org/10.1111/1471-0528.15638)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Peer reviewed version

**Published In:**

BJOG: An International Journal of Obstetrics and Gynaecology

**Publisher Rights Statement:**

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as

doi: 10.1111/1471-0528.15638

This article is protected by copyright. All rights reserved.

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.



DUSKO ILIC (Orcid ID : 0000-0003-1647-0026)

Article type : Commentary

## What can stem cell technology offer to IVF patients?

**Running head:** Stem cell technology and infertility treatment

**Dusko Ilic,<sup>a,b\*</sup> Evelyn E. Telfer,<sup>c</sup> Caroline Ogilvie,<sup>d</sup> Nikola Kolundzic,<sup>b</sup> Yacoub Khalaf,<sup>a,b</sup>**

<sup>a</sup>Assisted Conception Unit, Guy's Hospital, <sup>b</sup>Department of Women's and Children Health, School of Life Course Sciences, and <sup>d</sup>Department of Medical and Molecular Genetics, King's College London Faculty of Life Sciences and Medicine, London SE1 9RT, UK

<sup>c</sup>MRC Centre for Reproductive Health, Queen's Medical Research Institute, University of Edinburgh and Institute of Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, UK.

**\*Correspondence:** dusko.ilic@kcl.ac.uk

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/1471-0528.15638

This article is protected by copyright. All rights reserved.

Couples and individuals with fertility issues often embrace the latest advances in medical research and are open to pursuing novel interventions, even those which have little or no evidence concerning efficacy or safety. Stem cell research and regenerative medicine are among the most controversial areas of medical science that have emerged within the last decade, and hold up the hope of providing a panacea for almost any health issue, including fertility. Here, we provide a brief overview of what the stem cell field can offer to patients facing fertility issues, with the aim of helping patients and physicians to make informed decisions and to have a better insight into possible outcomes.

Among multiple types of stem cells, only patient-specific induced pluripotent stem cells (iPSC) and germline stem cells, either male spermatogonial stem cells (SSCs) or female ovarian/oogonial stem cells (OSC) have the potential to be used as therapeutic tools in infertility treatment (Figure 1).

### **iPSC and gametogenesis**

Most work in this area has been carried out using a mouse model. However, translation between mouse and human reproductive biology is not straightforward. Conditions and protocols that work for mice cannot be simply extrapolated to humans. From veterinary medicine, we know that there are species-specific differences in outcomes of much simpler procedures than differentiation of gametes from iPSC lines. For example, in vitro maturation (IVM) of oocytes and blastocyst development following intracytoplasmic sperm injection (ICSI) are relatively successful in cattle, but less so in horses.

Experiments in mice suggest that differentiating oocytes from human iPSCs might be easier than achieving spermatogenesis. However, we are still struggling even with terminal stages of oocyte growth and maturation. IVM is offered to the patients only in some cases and in a limited number of clinics. In vitro growth (IVG), a stage of oogenesis that occurs before IVM,

is a subject of intense research and it is not offered clinically. Only when we resolve the problems of accomplishing successful IVM and IVG in humans, we be able to differentiate oocytes from iPSCs or primordial germ cell-like cells (PGC-LC).

### **iPSC and chromosomal trisomy**

Reprogramming of fibroblasts from sterile trisomic (41, XXY and 41, XYY) mice led to generation of euploid iPSCs.<sup>1</sup> Such euploid iPSC were further differentiated into the male germ cell lineage and functional sperm, which has been used in intracytoplasmic sperm injection (ICSI) to produce chromosomally normal, fertile offspring. The phenomenon of trisomy-biased chromosome loss (TCL) during reprogramming was not restricted only to sex chromosomes, but has also been observed in iPSC from a Down syndrome mouse model.

TCL also occurs in humans as confirmed with cells from Down (47, XY,+21 or 47, XX,+21) and Klinefelter (47, XXY) syndromes. Isogenic euploid 46,XY and 46,XX iPSC lines derived from a male with Klinefelter syndrome (47, XXY) would provide a tool for genetic dissection of sexual polymorphism. The strategy will be only useful for 47,XXY males with complete azoospermia; Down syndrome males and females are usually fertile and produce euploid offspring. Regardless, in order to translate TCL into clinic, a complete gametogenesis has to be developed in vitro first. Although both oogenesis and spermatogenesis from iPSC lines have been successfully demonstrated in mice,<sup>2-5</sup> such attempts in humans are still rare and mostly futile.

### **SSCs and male infertility**

About 50% of infertility is attributable to the male and in a majority of cases is caused by impaired spermatogenesis. Spermatogenesis is a process in which SSCs undergo complex

cellular processes of meiosis, DNA compaction and flagellum formation. Reproducing these events in vitro has not been successful yet and there is no cellular replacement therapy available for men who suffer from azoospermia.

Finding that the transplantation of mouse spermatogonial stem cells from an infertile donor to a permissive testicular environment could restore fertility and result in progeny with the genetic makeup of the infertile male donor, raised the hopes of many infertile men.<sup>6</sup>

However, this is rather an exception than a rule. In this particular case, the defect causing infertility was azoospermia due to lack of a membrane-bound kit ligand (KITLG, known also as Steel factor or stem cell factor) on Sertoli cells. Spermatogonia from infertile testis with defective Sertoli cells transplanted into mice with a healthy testicular microenvironment was able to undergo spermatogenesis and form mature spermatozoa. Whether and how this strategy could be implemented and executed in infertile men carrying mutation in KITLG gene remains open for discussion. Novel genome editing technology based on clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated enzymes might be an option to repair the mutation.<sup>7</sup>

The most common genetic cause of male infertility, de novo deletion of one or more *azoospermia factor (AZF)* regions of human Y chromosome cannot be rescued with a similar strategy. This is due to the defect being in germ cells and not supportive cells. Indeed, human iPSC lines with deleted *AZF* region were compromised in germ cell development in vitro as well as in vivo, following xenotransplantation to murine seminiferous tubules.<sup>8</sup>

### **OSC and female fertility**

In addition to work on human embryonic stem cells (hESCs) and iPSCs to produce gametes in vitro, there have been several studies on isolating and developing putative OSCs from adult women.<sup>9-11</sup> For almost a century, there has been a debate surrounding the ability of

adult female mammals to undergo post-natal germ cell renewal. The current consensus is that the population of female germ cells (oocytes) is fixed before or around the time of birth, depending on species. In 2004 a study proposing germ cell renewal in adult female mice was published<sup>12</sup> and since then the isolation of mitotically active cells expressing germline markers has been reported from ovaries of adult rodents, cows, sheep, primates and humans. Development of these putative OSCs in-vitro and the generation of live young from fully differentiated rodent OSCs has also been described.

OSCs are characterised by expression of primitive germ cell-specific markers and high levels of telomerase. Cells with these characteristics have been isolated from human ovaries and cultured *in vitro* and they form what appear to be oocytes,<sup>9-11</sup> but, so far, the formation of meiotically functional oocytes from human OSCs has yet to be demonstrated.

Transplantation of in vitro expanded mouse OSCs back into germ cell depleted ovaries leads to the generation of fertilisation-competent eggs and the production of viable embryos and offspring. The physiological relevance of these cells to adult ovarian function and fertility remains to be determined and it may be that they are only activated under perturbed conditions that cause damage to the germ cells in vivo.

Whilst there remains controversy over the biological significance of these cells, it must be acknowledged that the identification and isolation of populations of cells with germ line potential within the adult human ovary represents a significant advance with the potential to improve infertility treatments. The most significant application of putative OSCs for human fertility would be to produce and develop oocytes in vitro.<sup>10</sup> Methodologies to grow human immature oocytes from primordial stages to mature oocytes entirely in vitro have been developed<sup>13</sup> and the technique of in vitro growth (IVG) could be combined with OSCs to support formation and growth entirely *in vitro*. In order to move this work forward, it is essential to demonstrate which cell populations can form oocytes when given the appropriate support and to demonstrate the developmental potential of the putative oocytes

derived from human OSCs. Many practical and conceptual obstacles remain before clinical application of OSC-based technologies can ever be fully realised, but it is important to move forward from the initial scepticism towards solid testing of the cells found within the adult human ovary.

### **Same sex partners and genetic parenthood**

The newest study using a combination of gametes and hypomethylated mouse embryonic stem cells (mESCs) with deletion of imprinted regions suggests that it might be possible to allow both members of a same-sex couple to become genetic parents.<sup>14</sup> To create bimaternal mice, the scientists deleted three imprinting regions of the genome from haploid female mESCs before injecting the cells into eggs from another female mouse. From 210 embryos, they produced 29 live mice (13.8%), which were physically normal, lived to adulthood, and had offspring of their own. Their cognitive capacity has not been assessed. Creation of bipaternal mice was more complicated and less successful. They deleted seven imprinting regions from haploid male mESCs. The edited haploid X-bearing mESCs and Y-bearing sperm from another male mouse were then injected together into eggs that had their nuclei, and therefore their female genetic material, removed. Although the resulting zygotes had mitochondria originating from the denucleated egg, the embryos created contained nuclear DNA only from the two male parents. None of 1184 bipaternal embryos developed beyond embryonic day (E)8.5 after transplantation into pseudopregnant female mice, and placental development did not pass E10.5. In an attempt to rescue the defects in the extraembryonic tissues, the authors derived androgenic diploid ESC lines from bipaternal embryos and combined them with tetraploid embryos. From 1023 such embryos, only 12 (1.2%) reached full-term, and these died shortly after birth. To consider exploring similar technology for human application in the near future is implausible. Imprinted genes differ between species and in humans the pattern is more complex than in mice. The risk of

severe abnormalities is too high, and it is likely to take years of research in various animal models to fully understand how this could be done safely.<sup>15</sup>

## **Summary**

Stem cell technology is not yet sufficiently advanced to provide treatments for infertile patients. Neither the use of germline stem cells to support in vivo gametogenesis, nor the production of in vitro gametes from germline stem cells or iPSC lines, is close to clinical implementation. Whilst there are still many barriers to recapitulating the processes and overcoming the limiting steps of gametogenesis pathways, animal studies have shown promising avenues for research, which may in time lead to clinical benefits.

## **Funding**

There are no funders to report for this submission

## **Contribution**

D.I. and E.T. wrote the first draft of the paper. C.O. and Y.K. critically reviewed the manuscript. N.K. contributed schematic drawing.

## **Conflict of interest**

The authors declare no conflict of interest. Completed disclosure of interest forms are available to view online as supporting information.

This article is protected by copyright. All rights reserved.



## References

- 1 Hirota T, Ohta H, Powell BE, Mahadevaiah SK, Ojarikre OA, Saitou M et al. Fertile offspring from sterile sex chromosome trisomic mice. *Science* 2017;357:932–935.
- 2 Hayashi K, Ohta H, Kurimoto K, Aramaki S, Saitou M. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. *Cell* 2011;146:519–532.
- 3 Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. *Science* 2012;338:971–975.
- 4 Hikabe O, Hamazaki N, Nagamatsu G, Obata Y, Hirao Y, Hamada N et al. Reconstitution in vitro of the entire cycle of the mouse female germ line. *Nature* 2016;539:299–303.
- 5 Zhou Q, Wang M, Yuan Y, Wang X, Fu R et al. Complete meiosis from embryonic stem cell-derived germ cells in vitro. *Cell Stem Cell* 2016;18:330–340.
- 6 Ogawa T, Dobrinski I, Avarbock MR, Brinster RL. Transplantation of male germ line stem cells restores fertility in infertile mice. *Nat Med* 2000;6:29–34.
- 7 Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. *Science* 2018;361:866–869.
- 8 Ramathal C, Durruthy-Durruthy J, Sukhwani M, Arakaki JE, Turek PJ et al. Fate of iPSCs derived from azoospermic and fertile men following xenotransplantation to murine seminiferous tubules. *Cell Rep* 2014;7:1284–1297.

- 9 White YA, Woods DC, Takai Y, Ishihara O, Seki H, Tilly JL. Oocyte formation by mitotically active germ cells purified from ovaries of reproductive-age women. *Nat Med* 2012;18:413–421
- 10 Anderson RA, Telfer EE. Being a good egg in the 21st century. *Br Med Bull* 2018;127:83–89.
- 11 Clarkson YL, McLaughlin M, Waterfall M, Dunlop CE, Skehel PA, Anderson RA et al. Initial characterisation of adult human ovarian cell populations isolated by DDX4 expression and aldehyde dehydrogenase activity. *Sci Rep* 2018;8:6953
- 12 Johnson J, Canning J, Kaneko T, Pru JK, Tilly JL. Germline stem cells and follicular renewal in the postnatal mammalian ovary. *Nature* 2004;428:145–150.
- 13 McLaughlin M, Albertini DF, Wallace WHB, Anderson RA, Telfer EE. Metaphase II oocytes from human unilaminar follicles grown in a multi-step culture system. *Mol Hum Reprod* 2018;24:135–142.
- 14 Li ZK, Wang LY, Wang LB, Feng GH, Yuan XW, Liu C et al. Generation of Uniparental Mice from Hypomethylated Haploid ESCs with Imprinting Region Deletions. *Cell Stem Cell* 2018; published on line Oct 11, 2018.
- 15 Ilic D, Ogilvie C, Noli L, Kolundzic N, Khalaf Y. Human embryos from induced pluripotent stem cell-derived gametes: ethical and quality considerations. *Regen Med* 2017;12:681–691.

## Figure legend

Figure 1. Patient-specific induced pluripotent stem cells (iPSC) and germline stem cells, either male spermatogonial stem cells (SSCs) or female ovarian/oogonial stem cells (OSC) have the potential to be used as therapeutic tools in infertility treatment. PGCs, primordial germ-cells.

